
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3045389/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis. Annals of Surgical Oncology, 2022, 29, 2324-2331.	1.5	14
2	ASO Author Reflections: Adjuvant Chemotherapy Should not be Omitted for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability. Annals of Surgical Oncology, 2022, 29, 2332-2333.	1.5	0
3	Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma. Liver International, 2022, 42, 674-681.	3.9	39
4	Cetuximab resistance induced by hepatocyte growth factor is overcome by MET inhibition in KRAS, NRAS, and BRAF wild-type colorectal cancers. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2995-3005.	2.5	5
5	Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group. Cancer Research and Treatment, 2022, 54, 1-9.	3.0	9
6	Clinical characteristics and disease course of splanchnic vein thrombosis in gastrointestinal cancers: A prospective cohort study. PLoS ONE, 2022, 17, e0261671.	2.5	4
7	Safety and efficacy of intraperitoneal paclitaxel plus systemic FOLFOX for gastric cancer with peritoneal metastasis: Phase I results Journal of Clinical Oncology, 2022, 40, 309-309.	1.6	0
8	Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress Journal of Clinical Oncology, 2022, 40, TPS621-TPS621.	1.6	0
9	Biomarker-oriented study of pembrolizumab in combination with chemotherapy in chemotherapy-naÃ ⁻ ve advanced pancreatic cancer: A phase 2 trial-in-progress Journal of Clinical Oncology, 2022, 40, TPS639-TPS639.	1.6	0
10	Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment: Trial in progress Journal of Clinical Oncology, 2022, 40, TPS490-TPS490.	1.6	2
11	Sex-based differences in histology, staging, and prognosis among 2983 gastric cancer surgery patients. World Journal of Gastroenterology, 2022, 28, 933-947.	3.3	14
12	Safety and Efficacy of Intraperitoneal Paclitaxel Plus Intravenous Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) for Gastric Cancer with Peritoneal Metastasis. Annals of Surgical Oncology, 2022, 29, 5084-5091.	1.5	8
13	Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. The Lancet Gastroenterology and Hepatology, 2022, 7, 522-532.	8.1	149
14	Treatment patterns of thrombopoietin receptor agonists among adults with primary immune thrombocytopenia: A Korean nationwide population-based study. Thrombosis Research, 2022, 213, 114-118.	1.7	0
15	ASO Visual Abstract: Safety and Efficacy of Intraperitoneal Paclitaxel Plus Intravenous Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) for Gastric Cancer with Peritoneal Metastasis. Annals of Surgical Oncology, 2022, , 1.	1.5	0
16	Performance of clinician prediction of survival in oncology outpatients with advanced cancer. PLoS ONE, 2022, 17, e0267467.	2.5	4
17	Effectiveness of oral fluoropyrimidine monotherapy as adjuvant chemotherapy for high-risk stage II colon cancer. Annals of Surgical Treatment and Research, 2022, 102, 271.	1.0	3
18	Health-related quality of life in patients treated with gemcitabine/cisplatin and durvalumab ± tremelimumab in chemotherapy-naÃ⁻ve advanced biliary tract cancer Journal of Clinical Oncology, 2022, 40, 4117-4117.	1.6	0

#	Article	IF	CITATIONS
19	Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC) Journal of Clinical Oncology, 2022, 40, 4075-4075.	1.6	7
20	Trastuzumab plus FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer: A multi-institutional phase II trial of the Korean Cancer Study Group (KCSG-HB19-14) Journal of Clinical Oncology, 2022, 40, 4096-4096.	1.6	1
21	Effectiveness of Combining Bevacizumab With First-Line Chemotherapy Regimens for Metastatic Colorectal Cancer in Real-World Practice. Clinical Colorectal Cancer, 2021, 20, 101-112.e6.	2.3	4
22	Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial). Gastric Cancer, 2021, 24, 156-167.	5.3	29
23	The prognostic role of soluble transforming growth factorâ€Î² and its correlation with soluble programmed deathâ€ligand 1 in biliary tract cancer. Liver International, 2021, 41, 388-395.	3.9	4
24	Pneumocystis jirovecii pneumonia in diffuse large Bâ€cell Lymphoma treated with Râ€CHOP. Mycoses, 2021, 64, 60-65.	4.0	7
25	A targetâ€mediated drug disposition population pharmacokinetic model of GC1118, a novel antiâ€EGFR antibody, in patients with solid tumors. Clinical and Translational Science, 2021, 14, 990-1001.	3.1	0
26	Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study. Cancers, 2021, 13, 331.	3.7	4
27	A single-arm feasibility study of gradual dose de-escalation of antiemetic dexamethasone for older patients receiving chemotherapy. Journal of Geriatric Oncology, 2021, 12, 922-929.	1.0	1
28	Different effects of p53 protein overexpression on the survival of gastric cancer patients according to Lauren histologic classification: a retrospective study. Gastric Cancer, 2021, 24, 844-857.	5.3	14
29	A phase II trial of trastuzumab plus modified-FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer (BTC): Multi-institutional study of the Korean Cancer Study Group (KCSG-HB19-14) Journal of Clinical Oncology, 2021, 39, TPS4161-TPS4161.	1.6	4
30	DNA-damage response-umbrella study of the combination of ceralasertib and olaparib, or ceralasertib and durvalumab in advanced biliary tract cancer: A phase 2 trial-in-progress Journal of Clinical Oncology, 2021, 39, TPS4166-TPS4166.	1.6	2
31	Adjuvant chemotherapy for gastric cancer patients with mismatch repair deficiency or microsatellite instability Journal of Clinical Oncology, 2021, 39, e16004-e16004.	1.6	0
32	Gastrointestinal cancer treatment with immune checkpoint inhibitors. Journal of the Korean Medical Association, 2021, 64, 342-348.	0.3	0
33	Correlation between tumor infiltrating immune cells and peripheral regulatory T cell determined using methylation analyses and its prognostic significance in resected gastric cancer. PLoS ONE, 2021, 16, e0252480.	2.5	7
34	The Enhanced Inhibitory Effect of Estrogen on PD-L1 Expression Following Nrf2 Deficiency in the AOM/DSS Model of Colitis-Associated Cancer. Frontiers in Oncology, 2021, 11, 679324.	2.8	4
35	A Prognostic Model to Facilitate Palliative Care Referral in Oncology Outpatients. Cancer Research and Treatment, 2021, , .	3.0	1
36	A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy. European Journal of Cancer, 2021, 154, 288-295.	2.8	26

#	Article	IF	CITATIONS
37	A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer. Journal of Cancer, 2021, 12, 912-917.	2.5	5
38	Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX. Journal of Personalized Medicine, 2021, 11, 83.	2.5	8
39	R-MPV followed by high-dose chemotherapy with thiotepa-based and autologous stem cell transplantation for newly diagnosed primary central nervous system lymphoma: a single-center experience. Blood Research, 2021, 56, 285-292.	1.3	3
40	Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer. Scientific Reports, 2021, 11, 23803.	3.3	4
41	The association between changes in symptoms or quality of life and overall survival in outpatients with advanced cancer. Annals of Palliative Medicine, 2021, .	1.2	1
42	Conversion Surgery in Metastatic Gastric Cancer and Cancer Dormancy as a Prognostic Biomarker. Cancers, 2020, 12, 86.	3.7	11
43	Polypharmacy, Inappropriate Medication Use, and Drug Interactions in Older Korean Patients with Cancer Receiving First-Line Palliative Chemotherapy. Oncologist, 2020, 25, e502-e511.	3.7	32
44	Symptom burden and characteristics of patients who die in the acute palliative care unit of a tertiary cancer center. Annals of Palliative Medicine, 2020, 9, 216-223.	1.2	4
45	PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer. Scientific Reports, 2020, 10, 12308.	3.3	20
46	Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 654-659.	1.3	18
47	PI3K p110α Blockade Enhances Anti-Tumor Efficacy of Abemaciclib in Human Colorectal Cancer Cells. Cancers, 2020, 12, 2500.	3.7	4
48	Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2399-2410.	2.5	10
49	Effect of Helicobacter pylori eradication after subtotal gastrectomy on the survival rate of patients with gastric cancer: follow-up for up to 15Âyears. Gastric Cancer, 2020, 23, 1051-1063.	5.3	20
50	Regorafenib in patients with advanced Childâ€Pugh B hepatocellular carcinoma: A multicentre retrospective study. Liver International, 2020, 40, 2544-2552.	3.9	32
51	Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: AÂrandomised phase III trial. European Journal of Cancer, 2020, 130, 51-62.	2.8	34
52	TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy. Cancers, 2020, 12, 334.	3.7	6
53	Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naÃ⁻ve advanced biliary tract cancer (aBTC) Journal of Clinical Oncology, 2020, 38, 4520-4520.	1.6	63
54	Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer. Cancer Research and Treatment, 2020, 52, 1178-1187.	3.0	12

#	Article	IF	CITATIONS
55	A randomized phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy Journal of Clinical Oncology, 2020, 38, 4603-4603.	1.6	5
56	Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: Multicenter study of the Korean Cancer Study Group (KCSG) Journal of Clinical Oncology, 2020, 38, 4624-4624.	1.6	0
57	A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01). Oncologist, 2019, 24, 18-e24.	3.7	25
58	Development and Validation of an Easy-to-Implement, Practical Algorithm for the Identification of Molecular Subtypes of Gastric Cancer: Prognostic and Therapeutic Implications. Oncologist, 2019, 24, e1321-e1330.	3.7	20
59	Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study. British Journal of Cancer, 2019, 121, 332-339.	6.4	19
60	A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors. Oncologist, 2019, 24, 1037-e636.	3.7	4
61	Prognostic implication of ABC transporters and cancer stem cell markers in patients with stage III colon cancer receiving adjuvant FOLFOX‑4 chemotherapy. Oncology Letters, 2019, 17, 5572-5580.	1.8	9
62	Clinical characteristics and outcomes of patients enrolled in clinical trials compared with those of patients outside clinical trials in advanced gastric cancer. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 158-165.	1.1	3
63	Serum biomarkers for predicting overall survival and early mortality in older patients with metastatic solid tumors. Journal of Geriatric Oncology, 2019, 10, 749-756.	1.0	13
64	Identification of a potentially avoidable cardiopulmonary resuscitation in hematology and oncology wards. BMC Palliative Care, 2019, 18, 93.	1.8	3
65	Trastuzumab Specific Epitope Evaluation as a Predictive and Prognostic Biomarker in Gastric Cancer Patients. Biomolecules, 2019, 9, 782.	4.0	7
66	Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement. Cells, 2019, 8, 1538.	4.1	7
67	Acute pulmonary thromboembolism caused by factor V Leiden mutation in South Korea. Medicine (United States), 2019, 98, e16318.	1.0	1
68	Incidence and predictors of venous thromboembolism in medically ill hospitalized elderly cancer patients: a prospective observational study. Supportive Care in Cancer, 2019, 27, 2507-2515.	2.2	8
69	Somatic mutational profiles of stage II and III gastric cancer according to tumor microenvironment immune type. Genes Chromosomes and Cancer, 2019, 58, 12-22.	2.8	11
70	Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer. Cancer Research and Treatment, 2019, 51, 223-239.	3.0	13
71	Prospective Validation of The Korean Cancer Study Group Geriatric Score (KG)-7, a Novel Geriatric Screening Tool, in Older Patients with Advanced Cancer Undergoing First-line Palliative Chemotherapy. Cancer Research and Treatment, 2019, 51, 1249-1256.	3.0	5
72	The prognostic role of soluble transforming growth factor-β (sTGFb) and soluble programmed death-ligand 1 (sPDL1) in biliary tract cancer patients treated with binimetinib and capecitabine Journal of Clinical Oncology, 2019, 37, 257-257.	1.6	0

#	Article	IF	CITATIONS
73	The prognostic role of soluble transforming growth factor-β related with soluble programmed death-ligand 1 in biliary tract cancer Journal of Clinical Oncology, 2019, 37, 4094-4094.	1.6	2
74	Symptom burden and characteristics of patients who die in the acute palliative care unit of a tertiary cancer center Journal of Clinical Oncology, 2019, 37, 53-53.	1.6	0
75	Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy. Annals of Oncology, 2018, 29, 1220-1226.	1.2	36
76	Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer, 2018, 21, 473-480.	5.3	21
77	S-1–Induced Lacrimal Drainage Obstruction and Its Association with Ingredients/Metabolites of S-1 in Tears and Plasma: A Prospective Multi-institutional Study. Cancer Research and Treatment, 2018, 50, 30-39.	3.0	12
78	Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer. PLoS ONE, 2018, 13, e0209104.	2.5	13
79	Effect of Early Adjuvant Chemotherapy on Survival of Advanced Gastric Cancer Patients: a Propensity Score-matched Analysis. Journal of Gastric Cancer, 2018, 18, 58.	2.5	9
80	A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study. PLoS ONE, 2018, 13, e0205853.	2.5	10
81	BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression. International Journal of Molecular Sciences, 2018, 19, 3164.	4.1	17
82	Impact of Tumor Regression Grade as a Major Prognostic Factor in Locally Advanced Rectal Cancer after Neoadjuvant Chemoradiotherapy: A Proposal for a Modified Staging System. Cancers, 2018, 10, 319.	3.7	45
83	Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study. PLoS ONE, 2018, 13, e0198544.	2.5	21
84	Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study. British Journal of Cancer, 2018, 118, 1169-1175.	6.4	25
85	Diagnostic Yield and False-Referral Rate of Staging Chest CT in Patients with Colon Cancer. Radiology, 2018, 289, 535-545.	7.3	10
86	Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells. Cancer Letters, 2018, 430, 123-132.	7.2	52
87	Phase Ib study of binimetinib (MEK162) in combination with capecitabine in gemcitabine-pretreated advanced biliary tract cancer Journal of Clinical Oncology, 2018, 36, 4079-4079.	1.6	1
88	Correlation between tumor infiltrating immune cells and peripheral regulatory T cell determined by methylation analyses and its prognostic significance in gastric cancer Journal of Clinical Oncology, 2018, 36, 66-66.	1.6	0
89	Liver and/or lung metastasectomy after cetuximab or bevacizumab+FOLFIRI chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2018, 36, 843-843.	1.6	0
90	Epidemiology and management of primary immune thrombocytopenia: A nationwide population-based study in Korea. Thrombosis Research, 2017, 155, 86-91.	1.7	46

#	Article	IF	CITATIONS
91	Prognostic value of p21â€activated kinase 4 in resected pancreatic cancer. Apmis, 2017, 125, 699-707.	2.0	12
92	Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity. European Journal of Cancer, 2017, 76, 125-133.	2.8	38
93	Multidisciplinary management of intrahepatic cholangiocarcinoma: Current approaches. Surgical Oncology, 2017, 26, 146-152.	1.6	40
94	Comparison of efficacy and tolerance between combination therapy and monotherapy as first-line chemotherapy in elderly patients with advanced gastric cancer: Study protocol for a randomized controlled trial. Contemporary Clinical Trials Communications, 2017, 8, 55-61.	1.1	1
95	Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. Clinical Cancer Research, 2017, 23, 5671-5678.	7.0	121
96	Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer. Gastric Cancer, 2017, 20, 602-611.	5.3	76
97	EGF Induced RET Inhibitor Resistance in <i>CCDC6-RET</i> Lung Cancer Cells. Yonsei Medical Journal, 2017, 58, 9.	2.2	30
98	Differences in the Clinical Characteristics of Rapid Response System Activation in Patients Admitted to Medical or Surgical Services. Journal of Korean Medical Science, 2017, 32, 688.	2.5	14
99	EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release. Oncotarget, 2017, 8, 63901-63910.	1.8	30
100	Korean red ginseng to improve cancer-related fatigue in colorectal cancer patients with FOLFOX chemotherapy: A randomized, double-blind, placebo-controlled, parallel, multicenter trial, NCT02039635 Journal of Clinical Oncology, 2017, 35, 10008-10008.	1.6	3
101	Updated results of a phase II study of gemcitabine, erlotinib, and S-1 in patients with advanced pancreatic cancer Journal of Clinical Oncology, 2017, 35, e15778-e15778.	1.6	2
102	Predicting cumulative incidence of chemotherapy toxicity in older patients with cancer: Korean Cancer Study Group prospective cohort study (KCSG) PC 13-09 Journal of Clinical Oncology, 2017, 35, e21539-e21539.	1.6	1
103	Early versus delayed initiation of adjuvant treatment for pancreatic cancer. PLoS ONE, 2017, 12, e0173960.	2.5	21
104	Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients. Oncotarget, 2017, 8, 26356-26367.	1.8	54
105	<i>PIK3CA</i> mutations are associated with increased tumor aggressiveness and Akt activation in gastric cancer. Oncotarget, 2017, 8, 90948-90958.	1.8	37
106	A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine. Cancer Research and Treatment, 2017, 49, 706-716.	3.0	17
107	Prospective validation of a novel geriatric screening tool, the Korean cancer study group geriatric score (KG)-7, in older patients with advanced cancer undergoing 1st line palliative chemotherapy Journal of Clinical Oncology, 2017, 35, e21540-e21540.	1.6	0
108	Preoperative chemoradiotherapy for elderly patients with locally advanced rectal cancer—a real-world outcome study. Japanese Journal of Clinical Oncology, 2016, 46, 1108-1117.	1.3	16

#	Article	IF	CITATIONS
109	Diffuse Large B-Cell Lymphoma in the Elderly: Real World Outcomes of Immunochemotherapy in Asian Population. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 503-510.e3.	0.4	7
110	Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer, 2016, 19, 42-52.	5.3	230
111	Phase II trial of dacomitinib in patients with HER2-positive gastric cancer. Gastric Cancer, 2016, 19, 1095-1103.	5.3	33
112	Population-based outcomes research on treatment patterns and impact of chemotherapy in older patients with metastatic gastric cancer. Journal of Cancer Research and Clinical Oncology, 2016, 142, 687-697.	2.5	12
113	A randomized, open-label, two-arm phase II trial comparing the efficacy of sequential ipilimumab (ipi) versus best supportive care (BSC) following first-line (1L) chemotherapy in patients with unresectable, locally advanced/metastatic (A/M) gastric or gastro-esophageal junction (G/GEJ) cancer Journal of Clinical Oncology, 2016, 34, 4011-4011.	1.6	34
114	Efficacy and safety findings from DREAM: A phase III study of DHP107 (oral paclitaxel) vs IV paclitaxel in patients with gastric cancer after failure of first-line chemotherapy Journal of Clinical Oncology, 2016, 34, 4016-4016.	1.6	3
115	Multidimensional Geriatric Prognostic Index, Based on a Geriatric Assessment, for Long-Term Survival in Older Adults in Korea. PLoS ONE, 2016, 11, e0147032.	2.5	12
116	Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment. PLoS ONE, 2016, 11, e0161278.	2.5	44
117	Transmissibility of the Campaign for Colorectal Cancer Awareness in Korea Among Twitter Users. Annals of Coloproctology, 2016, 32, 184.	2.0	12
118	Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells. Cancer Research and Treatment, 2016, 48, 355-364.	3.0	7
119	Prospective Study on the Incidence of Postoperative Venous Thromboembolism in Korean Patients with Colorectal Cancer. Cancer Research and Treatment, 2016, 48, 978-989.	3.0	16
120	Efficacy and safety of FOLFIRI regimen in elderly versus nonelderly patients with advanced colorectal and gastric cancer Journal of Clinical Oncology, 2016, 34, 701-701.	1.6	0
121	Clinical outcomes of patients enrolled in clinical trial compared with patients outside clinical trial in advanced gastric cancer Journal of Clinical Oncology, 2016, 34, 21-21.	1.6	Ο
122	Effect of Smad3/4 on chemotherapeutic drug sensitivity in colorectal cancer cells. Oncology Reports, 2015, 33, 185-192.	2.6	14
123	Effects of a DPP4 inhibitor on cisplatin-induced acute kidney injury: study protocol for a randomized controlled trial. Trials, 2015, 16, 239.	1.6	16
124	Impact of Intratumoral Expression Levels of Fluoropyrimidine-Metabolizing Enzymes on Treatment Outcomes of Adjuvant S-1 Therapy in Gastric Cancer. PLoS ONE, 2015, 10, e0120324.	2.5	7
125	A Novel Geriatric Screening Tool in Older Patients with Cancer: The Korean Cancer Study Group Geriatric Score (KG)-7. PLoS ONE, 2015, 10, e0138304.	2.5	10
126	Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer. Clinical Cancer Research, 2015, 21, 2520-2529.	7.0	59

#	Article	IF	CITATIONS
127	Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden. Thrombosis Research, 2015, 135, 846-851.	1.7	24
128	A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2015, 75, 1175-1182.	2.3	1
129	Phase I/II Study of Weekly Oraxol for the Second‣ine Treatment of Patients With Metastatic or Recurrent Gastric Cancer. Oncologist, 2015, 20, 896-897.	3.7	17
130	INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)—Final overall and subgroup results Journal of Clinical Oncology, 2015, 33, 4003-4003.	1.6	11
131	INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG), first results Journal of Clinical Oncology, 2015, 33, 9-9.	1.6	7
132	Five-Year Follow-up Study of Monoclonal Gammopathy of Undetermined Significance in a Korean Elderly Urban Cohort. Cancer Research and Treatment, 2015, 47, 215-220.	3.0	6
133	p21-Activated Kinase 4 (PAK4) as a Predictive Marker of Gemcitabine Sensitivity in Pancreatic Cancer Cell Lines. Cancer Research and Treatment, 2015, 47, 501-508.	3.0	29
134	A phase III study to compare efficacy and safety of DHP107 (oral paclitaxel) versus IV paclitaxel in patients with metastatic or recurrent gastric cancer after failure of first-line chemotherapy (DREAM) Journal of Clinical Oncology, 2015, 33, TPS4138-TPS4138.	1.6	0
135	Salvage Treatment with Intracerebrospinal Fluid Thiotepa in Patients with Leptomeningeal Metastasis After Failure of Methotrexate-based Treatment. Anticancer Research, 2015, 35, 5631-8.	1.1	4
136	Prevalence and Risk Factors for Iron Deficiency Anemia in the Korean Population: Results of the Fifth Korea National Health and Nutrition Examination Survey. Journal of Korean Medical Science, 2014, 29, 224.	2.5	56
137	Metastatic testicular tumor presenting as a scrotal hydrocele: An initial manifestation of pancreatic adenocarcinoma. Oncology Letters, 2014, 7, 1793-1795.	1.8	9
138	The early discontinuation of palliative chemotherapy in older patients with cancer. Supportive Care in Cancer, 2014, 22, 773-781.	2.2	38
139	Gastric cancer with initial bone metastasis: A distinct group of diseases with poor prognosis. European Journal of Cancer, 2014, 50, 2810-2821.	2.8	33
140	Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer. Cancer Chemotherapy and Pharmacology, 2013, 71, 1435-1443.	2.3	15
141	Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival. Gastric Cancer, 2013, 16, 581-589.	5.3	28
142	A Prospective Study on the Incidence of Postoperative Venous Thromboembolism in Korean Gastric Cancer Patients: An Inquiry into the Application of Western Guidelines to Asian Cancer Patients. PLoS ONE, 2013, 8, e61968.	2.5	18
143	A prospective study on the incidence of postoperative venous thromboembolism in Korean gastric cancer patients: An inquiry into the application of western guidelines to Asian cancer patients Journal of Clinical Oncology, 2013, 31, e15129-e15129.	1.6	Ο
144	The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Letters, 2008, 272, 296-306.	7.2	111